About
Profile
In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destr
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
NVCR
Recent Earnings
NovoCure GAAP EPS of -$0.36 misses by $0.07, revenue of $128.43M beats by $1.23M
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- NovoCure GAAP EPS of -$0.36 misses by $0.07, revenue of $128.43M beats by $1.23M
- NovoCure Q4 2022 Earnings Preview
- Novocure stock dips amid organizational changes as chief medical officer departs
- NovoCure defended at H.C. Wainwright despite earnings led selloff
- Novocure off 15% on preliminary Q4 results
- Why did NovoCure stock surge today? Phase 3 data for lung cancer candidate
- Novocure, Zai Lab surge as lung cancer therapy meets main goal in late-stage trial
- NovoCure takes off on Wells Fargo's optimism for LUNAR program
- NovoCure GAAP EPS of -$0.25 beats by $0.03, revenue of $130.99M misses by $2.39M
- NovoCure downgraded at Piper Sandler despite positive Phase 3 readout ahead
- Novocure creates new CNS focused franchise to renew growth in brain cancer business
- Novocure stock down 10% on wider-than-expected Q2 loss
- NovoCure GAAP EPS of -$0.23 misses by $0.09, revenue of $140.9M beats by $5.77M
- NovoCure Q2 2022 Earnings Preview
- Novocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trial
- NovoCure initiated at buy at Wainwright on base business expansion, phase 3 readouts
- NovoCure GAAP EPS of -$0.04 beats by $0.15, revenue of $137.55M beats by $3.26M
- NovoCure Q1 2022 Earnings Preview
- Novocure gets green light to continue late-stage ovarian cancer trial
- NovoCure GAAP EPS of -$0.25 misses by $0.15, revenue of $133.21M misses by $1.28M
Recent Earnings
NovoCure GAAP EPS of -$0.36 misses by $0.07, revenue of $128.43M beats by $1.23M
| Date | Price | Open | High | Low | Vol | ER | |||
|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | 76.58 | 76.45 |
79.22
|
76.36
|
647.53K | ||||
| Apr 28 | 77.18 | 78.61 |
78.61
|
71.83
|
660.76K | ||||
| Apr 27 | 76.95 | 78.04 |
80.71
|
75.85
|
631.90K | ||||
| Apr 26 | 77.96 | 82.71 |
83.26
|
77.65
|
572.23K | ||||
| Apr 25 | 83.33 | 78.44 |
83.34
|
78.22
|
429.66K | ||||
| Apr 22 | 79.21 | 83.25 |
83.32
|
78.30
|
542.56K | ||||
| Apr 21 | 83.65 | 85.66 |
87.13
|
82.87
|
845.13K | ||||
| Apr 20 | 85.03 | 82.81 |
85.62
|
80.76
|
531.31K | ||||
| Apr 19 | 82.44 | 77.97 |
84.83
|
77.86
|
563.22K | ||||
| Apr 18 | 78.48 | 84.24 |
84.24
|
77.80
|
468.87K | ||||
| Apr 14 | 84.24 | 86.84 |
87.19
|
83.78
|
383.89K | ||||
| Apr 13 | 86.79 | 82.00 |
86.88
|
81.85
|
359.09K | ||||
| Apr 12 | 82.60 | 83.98 |
86.46
|
82.00
|
424.45K | ||||
| Apr 11 | 82.24 | 83.70 |
85.48
|
81.50
|
303.53K | ||||
| Apr 8 | 86.05 | 85.43 |
87.21
|
84.19
|
389.21K | ||||
| Apr 7 | 86.03 | 84.86 |
88.14
|
83.79
|
351.78K | ||||
| Apr 6 | 85.30 | 85.44 |
85.70
|
82.71
|
454.11K | ||||
| Apr 5 | 87.10 | 90.15 |
90.15
|
86.35
|
444.50K | ||||
| Apr 4 | 89.90 | 88.46 |
90.63
|
87.24
|
670.15K | ||||
| Apr 1 | 87.66 | 83.00 |
87.71
|
82.10
|
624.31K | ||||
| Mar 31 | 82.85 | 83.75 |
84.89
|
82.45
|
399.41K | ||||
| Mar 30 | 84.07 | 84.01 |
86.15
|
83.18
|
377.63K | ||||